Puma Biotechnology Inc
Most Recent
ASCO 2019 Presentations: Late-Stage Breast Cancer Trials
The annual ASCO (American Society of Clinical Oncology) 2019 meeting will be held on May 31–June 4 in Chicago.
Analysts Expect Puma Biotechnology to Become Profitable in 2020
In its first-quarter earnings conference call, Puma Biotechnology (PBYI) highlighted its cash burn of $15 million in the first quarter.
Puma Biotechnology Reduced Guidance for NERLYNX Sales
During its first-quarter earnings conference call, Puma Biotechnology (PBYI) reduced its guidance for fiscal 2019 net sales of NERLYNX in the US market.
What Analysts Are Recommending for Puma Biotechnology
On May 10, Puma Biotechnology (PBYI) reported its first-quarter results.
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.
NERLYNX: Market Expansion and Label Expansion
Puma Biotechnology is studying NERLYNX in a Phase 3 NALA trial in the third line HER2-positive metastatic breast cancer indication.
NERLYNX: Major Growth Driver for PBYI
Puma Biotechnology (PBYI) reported net sales of $52.6 million for NERLYNX in the third quarter.
Puma Biotechnology: Revenue Projections for 2018
Puma Biotechnology expects NERLYNX’s net product revenues to be $175 million–$200 million for 2018.
Puma Biotechnology Enters into Collaboration with Strata Oncology
Puma Biotechnology and Strata Oncology are collaborating to evaluate the safety and efficacy of the kinase inhibitor drug neratinib.
How Analysts Are Rating Puma Biotechnology in July
On July 5, Puma Biotechnology (PBYI) stock closed at $58.75, which represents a 25% growth from its 52-week low of $47 on June 7.
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.
Chart in Focus: Spectrum Pharmaceuticals’ Financials
In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.
An Overview of Spectrum Pharmaceuticals’ Drug Pipeline
Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.
Analysts’ Recommendations for Spectrum Pharmaceuticals
Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.
XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps
In the small-cap space, the top ten stocks of XBI had an average return of -12.18% for the week ended September 25, 2015. This is similar to XBI’s top ten large-cap stocks that returned -12.15%.
XBI Moving Averages Are on the Rise
For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.